Transverse myelitis is an inflammatory disease characterized by damage to the spinal cord, resulting in damage to the myelin sheath of nerve fibers. The disease can cause a variety of neurological symptoms and lead to impaired motor and sensory functions. The clinical picture includes progressive weakness, paresis, impaired sensitivity and reflexes. These manifestations usually occur symmetrically on both sides of the body and can be both acute and chronic. Transverse myelitis most often results from a viral or bacterial infection, and can also be associated with autoimmune diseases.
History of the disease and interesting historical facts
Transverse myelitis was first described in the early 19th century, but it was not until the 20th century that more detailed studies of this pathology began. In the medical literature, one can find references to inflammatory diseases of the spinal cord, starting with the works of scientists such as Jean Martin Charcot and Sidney Sherrington. The main research is aimed at determining the etiology and pathogenesis of myelitis, but many unanswered questions still remain. Interesting facts include cases of outbreaks of the disease associated with influenza epidemics, when the incidence rate increased significantly. This emphasizes the importance of viral infection as a trigger for the development of transverse myelitis.
Epidemiology
The epidemiology of transverse myelitis remains the subject of active research. According to various observations, the incidence is about 1-4 cases per 100,000 population per year. Studies show that transverse myelitis can more often develop in young people aged 10 to 30 years, but it also occurs in older people. It has also been established that the risk of the disease in women is higher, which is associated with hormonal factors and autoimmune processes. An important point is that, depending on the region, the incidence can fluctuate significantly. There are also spikes in the incidence in the post-vaccination period, which requires further clinical and epidemiological monitoring.
Genetic predisposition to this disease
To date, several genetic factors have been identified that may contribute to the development of transverse myelitis. In particular, certain alleles of the major histocompatibility complex (HLA) have been associated with an increased risk of developing this disease. The most significant are the HLA-DR2 and HLA-DQ6 alleles. In addition, studies indicate the influence of polymorphisms of genes responsible for inflammatory processes and the immune response, such as the tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) genes. However, despite the identification of genetic markers, the exact mechanism of genetic predisposition has not yet been established, which requires further research.
Risk factors for the development of this disease
There are various risk factors that contribute to the development of transverse myelitis. These include:
- Viral infections: flu, HPV, Epstein-Barr and others.
- Autoimmune diseases: multiple sclerosis, systemic lupus erythematosus.
- Professional and environmental factors: contact with toxic substances, pesticides.
- Use of certain medications: some vaccines, drugs that affect the immune system.
An important aspect is that the disease can be caused by a combination of the above factors, as well as individual characteristics of the body. Increased stress levels and changes in the immune response can also worsen the condition.
Diagnosis of this disease
Diagnosis of transverse myelitis is based on the clinical picture, laboratory and radiological studies. The main symptoms are:
- Weakness in the limbs, manifested as paresis.
- Impaired sensitivity: numbness, tingling.
- Changes in reflexes.
- Pain syndrome.
Laboratory tests may include cerebrospinal fluid tests, which often show elevated protein levels and cellular reactions. Radiological examinations, such as spinal cord MRI, help identify inflammatory changes in the nerve tissue. In addition, differential diagnosis with other diseases, such as multiple sclerosis and infectious neuritis, which require a different approach to treatment, is an important step.
Treatment
Treatment of transverse myelitis should be comprehensive and individualized. The main strategies are:
- General treatment: bed rest, physical rehabilitation.
- Pharmacological treatment: corticosteroids, immunosuppressants, antihistamines.
- Surgical treatment: in extreme cases, such as spinal cord compression.
- Other types of treatment: physiotherapy, psychological support.
It is important to emphasize that early initiation of treatment significantly affects the prognosis and can reduce the risk of long-term complications.
List of medications used to treat this disease
Medicines used to treat transverse myelitis include:
- Methylprednisolone (corticosteroid)
- Azamtropine (immunosuppressant).
- Interferons (to control the immune response).
- Nonsteroidal anti-inflammatory drugs (for pain relief).
The choice of individual drugs depends on the severity of the disease, the presence of concomitant pathologies and the general clinical situation.
Disease monitoring
Monitoring the condition of a patient with transverse myelitis includes control stages aimed at assessing the dynamics of the disease. The prognosis may vary from complete restoration of function to the development of permanent disability:
- Regular neurological examinations.
- Checking laboratory parameters of blood and cerebrospinal fluid.
- Assessment of motor and sensory functions.
Complications may include chronic pain, spasticity, urinary and defecation disorders. Good monitoring allows timely intervention and treatment adjustments.
Age-related features of the disease
Transverse myelitis can present differently depending on the age of the patient. In children, the disease is often acute and can lead to rapid loss of motor skills, but with a good chance of full recovery. In older patients, the disease can develop slowly and be more severe, associated with multiple chronic diseases and an increased likelihood of complications. It is important to consider age-related differences when developing both diagnostic and therapeutic strategies.
Questions and Answers
- What is transverse myelitis? It is an inflammatory disease of the spinal cord that leads to impairment of motor and sensory functions.
- What are the main symptoms of transverse myelitis? The main symptoms include weakness in the limbs, sensory disturbances and changes in reflexes.
- How is transverse myelitis diagnosed? Diagnosis includes clinical examination, laboratory tests and MRI of the spinal cord.
- What treatments are available for transverse myelitis? Treatment includes corticosteroids, immunosuppressants, physical rehabilitation, and in some cases surgery.
- What is the prognosis for transverse myelitis? The prognosis varies from complete recovery to disability, depending on the timeliness and adequacy of treatment.
